Share Email Print
cover

Proceedings Paper

Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes
Author(s): Tamar Dreifuss; Menachem Motiei; Oshra Betzer; Aron Popovtzer; Galith Abourbeh; Eyal Mishani; Rachela Popovtzer
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The highly used cancer imaging technique, [18F]FDG-PET, is based on the increased glucose metabolic activity in tumors. However, since there are other biological processes that exhibit increased metabolic activity, in particular inflammation, this methodology is prone to non-specificity for cancer. Herein we describe the development of a novel nanoparticle-based approach, utilizes Glucose-Functionalized Gold Nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our method has demonstrated specific tumor targeting and has successfully differentiated between cancer and inflammation in a combined tumor-inflammation mouse model, due to dissimilarities in vasculatures in different pathologic conditions. This novel approach provides new capabilities in cancer imaging, and can be applicable to a wide range of cancers.

Paper Details

Date Published: 22 February 2017
PDF: 9 pages
Proc. SPIE 10077, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV, 100770I (22 February 2017); doi: 10.1117/12.2249850
Show Author Affiliations
Tamar Dreifuss, Bar-Ilan Univ. (Israel)
Menachem Motiei, Bar-Ilan Univ. (Israel)
Oshra Betzer, Bar-Ilan Univ. (Israel)
Aron Popovtzer, Rabin Medical Ctr. (Israel)
Galith Abourbeh, Hadassah-Hebrew Univ. Hospital (Israel)
Eyal Mishani, Hadassah-Hebrew Univ. Hospital (Israel)
Rachela Popovtzer, Bar-Ilan Univ. (Israel)


Published in SPIE Proceedings Vol. 10077:
Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV
Alexander N. Cartwright; Dan V. Nicolau; Dror Fixler, Editor(s)

© SPIE. Terms of Use
Back to Top